Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.

Molecular Oncology
Chen YaoZhang-ping Gu

Abstract

Elucidation of the mechanisms of chemo-resistance and implementation of strategies to overcome it will be pivotal to improve the survival for osteosarcoma (OS) patients. We here suggest that sphingosine kinase-1 (SphK1) might be the key factor contributing to chemo-resistance in OS. Our Western-blots and immunohistochemistry results showed that SphK1 is over-expressed in multiple clinical OS tissues. Over-expression of SphK1 in OS cell line U2OS promoted its growth and endorsed its resistance against doxorubicin, while knocking-down of SphK1 by shRNA inhibited U2OS cell growth and increased its sensitivity to doxorubicin. Co-administration phenoxodiol with doxorubicin synergistically inhibited SphK1 activity to trigger cellular ceramide accumulation, and achieved synergistic anti-OS growth effect, accompanied with a significant increased of apoptosis and cytotoxicity. Increased cellular level of ceramide by the co-administration induced the association between Akt and Protein Phosphatase 1 (PP1) to dephosphorylate Akt, and to introduce a constitutively active Akt (CA-Akt) restored Akt activation and diminished cell growth inhibition. Further, phenoxodiol and doxorubicin synergistically activated apoptosis signal-regulating kina...Continue Reading

References

Mar 10, 1998·Proceedings of the Society for Experimental Biology and Medicine·C A LamartiniereN M Brown
Apr 29, 1998·Annual Review of Physiology·R N Kolesnick, M Krönke
Jan 23, 1999·Oncogene·S Basu, R Kolesnick
May 29, 2002·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·B Ogretmen, Y A Hannun
Jan 18, 2003·Biochimica Et Biophysica Acta·Michael MaceykaSarah Spiegel
Nov 25, 2003·Cancer Investigation·Fazlul H Sarkar, Yiwei Li
Mar 12, 2004·Cancer Letters·C Patrick ReynoldsRichard N Kolesnick
Jun 14, 2005·The Journal of Biological Chemistry·Nitai C HaitSarah Spiegel
Dec 15, 2005·International Journal of Cancer. Journal International Du Cancer·Jennifer R GambleMathew A Vadas
Jul 13, 2006·Expert Review of Anticancer Therapy·Alexander J Chou, Richard Gorlick
Oct 7, 2006·British Journal of Cancer·R A Sabbadini
Jan 24, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Regina AlemanyDagmar Meyer Zu Heringdorf
Mar 3, 2007·Apoptosis : an International Journal on Programmed Cell Death·Song JinJia-Guo Zhou
Sep 15, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Barbara S PaughTomasz Kordula
May 22, 2008·Cancer Letters·Sanjeev BanerjeeFazlul H Sarkar
Jul 22, 2008·Biochimica Et Biophysica Acta·Mathew VadasJennifer Gamble
Aug 12, 2008·Current Drug Targets·Dai ShidaSarah Spiegel
Aug 13, 2008·Cellular Signalling·Taro OkadaShun-ichi Nakamura
Sep 30, 2010·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Menno van LummelGerben A Koning
Jan 5, 2011·Gut·Hephzibah Rani S TagaramKevin F Staveley-O'Carroll

❮ Previous
Next ❯

Citations

Nov 6, 2013·Cancer Chemotherapy and Pharmacology·Lei GongGao-jue Wu
May 20, 2014·The Journal of Clinical Investigation·Yujin ZhangYang Xia
Mar 22, 2014·Neurotoxicity Research·Tânia CapelôaAna P Silva
Oct 31, 2015·Biochemical and Biophysical Research Communications·Haibin Jiang, Zhiyuan Zeng
Oct 28, 2015·Biochemical and Biophysical Research Communications·Lei ZhaiBo Zhang
Nov 26, 2015·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Almokhtar A AdwasAmany A Eissa
Mar 13, 2016·Biochemical and Biophysical Research Communications·Ying ZouXuemin Wang
Aug 16, 2015·Tissue & Cell·Ahmed M KabelHany M Borg
Feb 28, 2016·Biochemical and Biophysical Research Communications·Lin XuYunfeng Fu
Aug 22, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Dan ZhangBo Fang
Aug 26, 2014·Biochemical and Biophysical Research Communications·Xinhui ZhuZhiming Cui
Jul 30, 2014·Biochemical and Biophysical Research Communications·Yun-Rong ZhuYun-Qing Zhang
Jun 3, 2016·Biochemical and Biophysical Research Communications·Jun ZhuWeiguo Zhao
Mar 22, 2018·Oncotarget·Yan XuYu Yang
Aug 16, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Jin-Peng HeJie-Xiong Feng
Jun 15, 2019·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Ke WeiHaihao Wu
Jul 8, 2019·Naunyn-Schmiedeberg's Archives of Pharmacology·Madeline FinkFlorian Lang
Jul 27, 2021·Current Therapeutic Research, Clinical and Experimental·Koba KiknavelidzeGraham Kelly
Jun 24, 2021·The Journal of Pharmacology and Experimental Therapeutics·Asvelt J NduwumwamiJong K Yun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.